<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577824</url>
  </required_header>
  <id_info>
    <org_study_id>H8O-JE-GWBB</org_study_id>
    <nct_id>NCT00577824</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)</brief_title>
  <official_title>Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This long term, placebo-controlled trial is intended to assess the efficacy and safety of
      exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with
      oral antidiabetic(s) but not well controlled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Change in HbA1c from baseline following 24 weeks of treatment (i.e., HbA1c at week 24 minus HbA1c at week 0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving HbA1c &lt; 7.0%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of subjects whose HbA1c was &gt;=7.0% at baseline who achieved an HbA1c &lt; 7.0% at endpoint (i.e., number of eligible subjects who achieved HbA1c &lt; 7.0% divided by total number of eligible subjects times 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving HbA1c &lt; 6.5%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of subjects whose HbA1c was &gt;=6.5% at baseline who achieved an HbA1c &lt; 6.5% at endpoint (i.e., number of eligible subjects who achieved HbA1c &lt; 6.5% divided by total number of eligible subjects times 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in fasting blood glucose from baseline to endpoint (i.e., fasting blood glucose at week 24 minus fasting blood glucose at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in body weight form baseline to endpoint (i.e., body weight at week 24 minus body weight at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in total cholesterol from baseline to endpoint (i.e., total cholesterol at week 24 minus total cholesterol at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in LDL-C from baseline to endpoint (i.e., LDL-C at week 24 minus LDL-C at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in HDL-C from baseline to endpoint (i.e., HDL-C at week 24 minus HDL-C at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in triglycerides from baseline to endpoint (i.e., triglycerides at week 24 minus triglycerides at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Size</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in waist size from baseline to endpoint (i.e., waist size at week 24 minus waist size at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist-to-hip Ratio</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in waist-to-hip ratio from baseline to endpoint (i.e., waist-to-hip ratio at week 24 minus waist-to-hip ratio at week 0). Waist-to-hip ratio is waist circumference divided by hip circumference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 Point Self-monitored Blood Glucose (SMBG) Profiles at Baseline and Week 24</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Self-monitored blood glucose at 7 different time points during the day (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment - Beta Cell Function (HOMA-B)</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in HOMA-B from baseline to endpoint (i.e., HOMA-B at week 24 minus HOMA-B at week 0). HOMA-B is a measurement of beta cell function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment - Insulin Resistance (HOMA-R)</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in HOMA-R from baseline to endpoint (i.e., HOMA-R at week 24 minus HOMA-R at week 0). HOMA-R is a measurement of insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Insulin</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in serum insulin from baseline to endpoint (i.e., serum insulin at week 24 minus serum insulin at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-peptide</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in C-peptide from baseline to endpoint (i.e., C-peptide at week 24 minus C-peptide at week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 1,5-anhydroglucitol</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Change in 1,5-anhydroglucitol from baseline to endpoint (i.e., 1,5-anhydroglucitol at week 24 minus 1,5-anhydroglucitol at week 0)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>subcutaneous injection, 5mcg, twice a day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>LY2148568</other_name>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>subcutaneous injection, 10mcg, twice a day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>LY2148568</other_name>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes.

          -  Has been treated by sulfonylurea (SU) alone, SU and biguanide, or SU and
             thiazolidinedione for at least 90 days prior to study start. In a patient receiving SU
             alone, the dose must be within the dose range from maximum maintenance dose to maximum
             approved dose. The patients with concomitant use of alpha glucosidase inhibitors
             (acarbose, voglibose or miglitol) or meglitinide derivatives (mitiglinide or
             nateglinide) can be included in this study, but these drugs must be discontinued at
             study start.

          -  Have HbA1c 7.0% to 10% at study start.

          -  Have a body weight &gt;=50 kg.

        Exclusion Criteria:

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Have participated in this study previously or any other study using exenatide or
             glucagon-like peptide-1 (GLP-1) analogs within the last 90 days.

          -  Have been treated with any exogenous insulin within 90 days before study start.

          -  Have been continuously treated with any drug that directly affects gastrointestinal
             motility for more than a total of 21 days in the 90 days prior to study start.

          -  The combination therapy of sulfonylurea, biguanide and thiazolidinedione is not
             allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibaragi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com/</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <results_reference>
    <citation>Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, Boardman MK, Sowa H. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Investig. 2011 Jun 5;2(3):210-7. doi: 10.1111/j.2040-1124.2010.00084.x.</citation>
    <PMID>24843486</PMID>
  </results_reference>
  <results_reference>
    <citation>Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T. Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. J Diabetes Investig. 2011 Nov 30;2(6):448-56. doi: 10.1111/j.2040-1124.2011.00137.x.</citation>
    <PMID>24843529</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <results_first_submitted>November 23, 2009</results_first_submitted>
  <results_first_submitted_qc>November 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2009</results_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>exenatide</keyword>
  <keyword>LY2148568</keyword>
  <keyword>Byetta</keyword>
  <keyword>Lilly</keyword>
  <keyword>Amylin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5mcg Exenatide BID</title>
          <description>exenatide SC 5mcg, twice daily</description>
        </group>
        <group group_id="P2">
          <title>10mcg Exenatide BID</title>
          <description>exenatide SC 10mcg, twice daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo BID</title>
          <description>placebo SC, twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72">Started=Randomized</participants>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="72">Full Analysis Set=subject received at least one dose of study medication (active or placebo)</participants>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5mcg Exenatide BID</title>
          <description>exenatide SC 5mcg, twice daily</description>
        </group>
        <group group_id="B2">
          <title>10mcg Exenatide BID</title>
          <description>exenatide SC 10mcg, twice daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo BID</title>
          <description>placebo SC, twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="179"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="9.33"/>
                    <measurement group_id="B2" value="59.4" spread="9.75"/>
                    <measurement group_id="B3" value="56.3" spread="11.41"/>
                    <measurement group_id="B4" value="58.4" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24</title>
        <description>Change in HbA1c from baseline following 24 weeks of treatment (i.e., HbA1c at week 24 minus HbA1c at week 0)</description>
        <time_frame>baseline, 24 weeks</time_frame>
        <population>Full analysis set; Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24</title>
          <description>Change in HbA1c from baseline following 24 weeks of treatment (i.e., HbA1c at week 24 minus HbA1c at week 0)</description>
          <population>Full analysis set; Last observation carried forward.</population>
          <units>Percentage of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.11"/>
                    <measurement group_id="O2" value="-1.62" spread="0.11"/>
                    <measurement group_id="O3" value="-0.28" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Bonferroni's method was used to adjustment for multiplicity, and significant level was set to 2.5%(two-sided).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment group as a factor and baseline value as the covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving HbA1c &lt; 7.0%</title>
        <description>Percentage of subjects whose HbA1c was &gt;=7.0% at baseline who achieved an HbA1c &lt; 7.0% at endpoint (i.e., number of eligible subjects who achieved HbA1c &lt; 7.0% divided by total number of eligible subjects times 100)</description>
        <time_frame>24 weeks</time_frame>
        <population>Full analysis set; Last observation carried forward. Only those patients with HbA1c &gt;=7% at baseline included.</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving HbA1c &lt; 7.0%</title>
          <description>Percentage of subjects whose HbA1c was &gt;=7.0% at baseline who achieved an HbA1c &lt; 7.0% at endpoint (i.e., number of eligible subjects who achieved HbA1c &lt; 7.0% divided by total number of eligible subjects times 100)</description>
          <population>Full analysis set; Last observation carried forward. Only those patients with HbA1c &gt;=7% at baseline included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="71.0"/>
                    <measurement group_id="O3" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Armitage</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving HbA1c &lt; 6.5%</title>
        <description>Percentage of subjects whose HbA1c was &gt;=6.5% at baseline who achieved an HbA1c &lt; 6.5% at endpoint (i.e., number of eligible subjects who achieved HbA1c &lt; 6.5% divided by total number of eligible subjects times 100)</description>
        <time_frame>24 weeks</time_frame>
        <population>Full analysis set; Last observation carried forward. Only subjects whose HbA1c was &gt;=6.5% at baseline were included.</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving HbA1c &lt; 6.5%</title>
          <description>Percentage of subjects whose HbA1c was &gt;=6.5% at baseline who achieved an HbA1c &lt; 6.5% at endpoint (i.e., number of eligible subjects who achieved HbA1c &lt; 6.5% divided by total number of eligible subjects times 100)</description>
          <population>Full analysis set; Last observation carried forward. Only subjects whose HbA1c was &gt;=6.5% at baseline were included.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Armitage</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Blood Glucose</title>
        <description>Change in fasting blood glucose from baseline to endpoint (i.e., fasting blood glucose at week 24 minus fasting blood glucose at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full analysis set; Last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Blood Glucose</title>
          <description>Change in fasting blood glucose from baseline to endpoint (i.e., fasting blood glucose at week 24 minus fasting blood glucose at week 0)</description>
          <population>Full analysis set; Last observation carried forward</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="3.83"/>
                    <measurement group_id="O2" value="-29.0" spread="3.81"/>
                    <measurement group_id="O3" value="-7.6" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.002</p_value>
            <p_value_desc>No adjustment for multiplicity. Significance level was 5% (two-sided).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Change in body weight form baseline to endpoint (i.e., body weight at week 24 minus body weight at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full analysis set; Last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Change in body weight form baseline to endpoint (i.e., body weight at week 24 minus body weight at week 0)</description>
          <population>Full analysis set; Last observation carried forward</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.28"/>
                    <measurement group_id="O2" value="-1.54" spread="0.27"/>
                    <measurement group_id="O3" value="-0.47" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>No adjustment for multiplicity. Significance level was 5% (two-sided).</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol</title>
        <description>Change in total cholesterol from baseline to endpoint (i.e., total cholesterol at week 24 minus total cholesterol at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full analysis set; Last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol</title>
          <description>Change in total cholesterol from baseline to endpoint (i.e., total cholesterol at week 24 minus total cholesterol at week 0)</description>
          <population>Full analysis set; Last observation carried forward</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.45" spread="3.36"/>
                    <measurement group_id="O2" value="-7.01" spread="3.13"/>
                    <measurement group_id="O3" value="-4.80" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.672</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low Density Lipoprotein Cholesterol (LDL-C)</title>
        <description>Change in LDL-C from baseline to endpoint (i.e., LDL-C at week 24 minus LDL-C at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full analysis set; Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low Density Lipoprotein Cholesterol (LDL-C)</title>
          <description>Change in LDL-C from baseline to endpoint (i.e., LDL-C at week 24 minus LDL-C at week 0)</description>
          <population>Full analysis set; Last observation carried forward.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.89" spread="3.01"/>
                    <measurement group_id="O2" value="-5.03" spread="2.45"/>
                    <measurement group_id="O3" value="-2.66" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.580</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High Density Lipoprotein Cholesterol (HDL-C)</title>
        <description>Change in HDL-C from baseline to endpoint (i.e., HDL-C at week 24 minus HDL-C at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full analysis set; Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High Density Lipoprotein Cholesterol (HDL-C)</title>
          <description>Change in HDL-C from baseline to endpoint (i.e., HDL-C at week 24 minus HDL-C at week 0)</description>
          <population>Full analysis set; Last observation carried forward.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.63" spread="0.91"/>
                    <measurement group_id="O2" value="-4.22" spread="0.70"/>
                    <measurement group_id="O3" value="-0.97" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>Change in triglycerides from baseline to endpoint (i.e., triglycerides at week 24 minus triglycerides at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full analysis set; Last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>Change in triglycerides from baseline to endpoint (i.e., triglycerides at week 24 minus triglycerides at week 0)</description>
          <population>Full analysis set; Last observation carried forward</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="15.59"/>
                    <measurement group_id="O2" value="4.13" spread="8.03"/>
                    <measurement group_id="O3" value="-4.60" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.490</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Size</title>
        <description>Change in waist size from baseline to endpoint (i.e., waist size at week 24 minus waist size at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Size</title>
          <description>Change in waist size from baseline to endpoint (i.e., waist size at week 24 minus waist size at week 0)</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.36"/>
                    <measurement group_id="O2" value="-1.81" spread="0.46"/>
                    <measurement group_id="O3" value="0.41" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist-to-hip Ratio</title>
        <description>Change in waist-to-hip ratio from baseline to endpoint (i.e., waist-to-hip ratio at week 24 minus waist-to-hip ratio at week 0). Waist-to-hip ratio is waist circumference divided by hip circumference.</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist-to-hip Ratio</title>
          <description>Change in waist-to-hip ratio from baseline to endpoint (i.e., waist-to-hip ratio at week 24 minus waist-to-hip ratio at week 0). Waist-to-hip ratio is waist circumference divided by hip circumference.</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>ratio (cm/cm)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0016" spread="0.0047"/>
                    <measurement group_id="O2" value="-0.0108" spread="0.0047"/>
                    <measurement group_id="O3" value="-0.0007" spread="0.0061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7 Point Self-monitored Blood Glucose (SMBG) Profiles at Baseline and Week 24</title>
        <description>Self-monitored blood glucose at 7 different time points during the day (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime).</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>7 Point Self-monitored Blood Glucose (SMBG) Profiles at Baseline and Week 24</title>
          <description>Self-monitored blood glucose at 7 different time points during the day (glucose measurements before and 2 hours after the start of the morning, midday, and evening meals, and at bedtime).</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes prior to breakfast SMBG at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" spread="36.3"/>
                    <measurement group_id="O2" value="175" spread="40.9"/>
                    <measurement group_id="O3" value="170" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes prior to breakfast SMBG at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" spread="36.4"/>
                    <measurement group_id="O2" value="140" spread="32.2"/>
                    <measurement group_id="O3" value="167" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr post-breakfast SMBG at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261" spread="50.5"/>
                    <measurement group_id="O2" value="263" spread="55.1"/>
                    <measurement group_id="O3" value="254" spread="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr post-breakfast SMBG at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" spread="61.1"/>
                    <measurement group_id="O2" value="149" spread="54.4"/>
                    <measurement group_id="O3" value="257" spread="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes prior to lunch SMBG at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="48.4"/>
                    <measurement group_id="O2" value="189" spread="68.4"/>
                    <measurement group_id="O3" value="179" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes prior to lunch SMBG at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" spread="43.9"/>
                    <measurement group_id="O2" value="152" spread="41.3"/>
                    <measurement group_id="O3" value="182" spread="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr post-lunch SMBG at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" spread="62.7"/>
                    <measurement group_id="O2" value="268" spread="62.4"/>
                    <measurement group_id="O3" value="264" spread="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr post-lunch SMBG at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" spread="63.2"/>
                    <measurement group_id="O2" value="195" spread="60.7"/>
                    <measurement group_id="O3" value="254" spread="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes prior to dinner SMBG at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" spread="53.7"/>
                    <measurement group_id="O2" value="176" spread="51.4"/>
                    <measurement group_id="O3" value="173" spread="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes prior to dinner SMBG at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="45.1"/>
                    <measurement group_id="O2" value="140" spread="35.5"/>
                    <measurement group_id="O3" value="181" spread="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr post-dinner SMBG at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" spread="53.4"/>
                    <measurement group_id="O2" value="247" spread="63.6"/>
                    <measurement group_id="O3" value="239" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2hr post-dinner SMBG at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="62.8"/>
                    <measurement group_id="O2" value="141" spread="57.7"/>
                    <measurement group_id="O3" value="247" spread="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bedtime SMBG at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" spread="53.7"/>
                    <measurement group_id="O2" value="225" spread="66.2"/>
                    <measurement group_id="O3" value="206" spread="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bedtime SMBG at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" spread="48.9"/>
                    <measurement group_id="O2" value="151" spread="44.3"/>
                    <measurement group_id="O3" value="212" spread="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment - Beta Cell Function (HOMA-B)</title>
        <description>Change in HOMA-B from baseline to endpoint (i.e., HOMA-B at week 24 minus HOMA-B at week 0). HOMA-B is a measurement of beta cell function.</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment - Beta Cell Function (HOMA-B)</title>
          <description>Change in HOMA-B from baseline to endpoint (i.e., HOMA-B at week 24 minus HOMA-B at week 0). HOMA-B is a measurement of beta cell function.</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.475" spread="10.566"/>
                    <measurement group_id="O2" value="6.836" spread="13.858"/>
                    <measurement group_id="O3" value="-0.707" spread="3.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment - Insulin Resistance (HOMA-R)</title>
        <description>Change in HOMA-R from baseline to endpoint (i.e., HOMA-R at week 24 minus HOMA-R at week 0). HOMA-R is a measurement of insulin resistance.</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment - Insulin Resistance (HOMA-R)</title>
          <description>Change in HOMA-R from baseline to endpoint (i.e., HOMA-R at week 24 minus HOMA-R at week 0). HOMA-R is a measurement of insulin resistance.</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.541" spread="0.402"/>
                    <measurement group_id="O2" value="-0.366" spread="0.188"/>
                    <measurement group_id="O3" value="-0.375" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.974</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Insulin</title>
        <description>Change in serum insulin from baseline to endpoint (i.e., serum insulin at week 24 minus serum insulin at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Insulin</title>
          <description>Change in serum insulin from baseline to endpoint (i.e., serum insulin at week 24 minus serum insulin at week 0)</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>mcU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.03"/>
                    <measurement group_id="O2" value="0.2" spread="3.42"/>
                    <measurement group_id="O3" value="-0.7" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-peptide</title>
        <description>Change in C-peptide from baseline to endpoint (i.e., C-peptide at week 24 minus C-peptide at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-peptide</title>
          <description>Change in C-peptide from baseline to endpoint (i.e., C-peptide at week 24 minus C-peptide at week 0)</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.11"/>
                    <measurement group_id="O2" value="0.07" spread="0.07"/>
                    <measurement group_id="O3" value="-0.08" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 1,5-anhydroglucitol</title>
        <description>Change in 1,5-anhydroglucitol from baseline to endpoint (i.e., 1,5-anhydroglucitol at week 24 minus 1,5-anhydroglucitol at week 0)</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Full Analysis Set; Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>5mcg Exenatide BID</title>
            <description>exenatide SC 5mcg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>10mcg Exenatide BID</title>
            <description>exenatide SC 10mcg, twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>placebo SC, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 1,5-anhydroglucitol</title>
          <description>Change in 1,5-anhydroglucitol from baseline to endpoint (i.e., 1,5-anhydroglucitol at week 24 minus 1,5-anhydroglucitol at week 0)</description>
          <population>Full Analysis Set; Last Observation Carried Forward</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="0.55"/>
                    <measurement group_id="O2" value="4.52" spread="0.54"/>
                    <measurement group_id="O3" value="0.66" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 weeks (Up to a 6 week screening period, and then 24 weeks on treatment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5mcg Exenatide BID</title>
          <description>exenatide SC 5mcg, twice daily</description>
        </group>
        <group group_id="E2">
          <title>10mcg Exenatide BID</title>
          <description>exenatide SC 10mcg, twice daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo BID</title>
          <description>placebo SC, twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric mucosal lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Ohman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

